Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008264 | 0.90 | LMNA (0.45) | KDM4EHSD17B10HPGDALDH1A1GLA | |
| SCHEMBL1007301 | 0.83 | KDM4E (0.56) | KDM4EHSD17B10HPGDALDH1A1GLA | |
| SCHEMBL20798579 | 0.80 | CSNK2A1 (0.56) | KDM4EHSD17B10HPGDALDH1A1GLA | |
| SCHEMBL1924374 | 0.78 | KDM4E (0.64) | KDM4EHSD17B10HPGDALDH1A1MAPK1 | |
| SCHEMBL27116432 | 0.78 | CDK2 (0.46) | KDM4EHSD17B10HPGDALDH1A1GLA | |
| SCHEMBL1009507 | 0.75 | CSNK2A1 (0.67) | KDM4EHSD17B10HPGDALDH1A1GLA | |
| SCHEMBL1924384 | 0.74 | CDK2 (0.54) | KDM4EHSD17B10HPGDALDH1A1MAPK1 | |
| SCHEMBL313181 | 0.74 | CSNK2A1 (0.56) | KDM4EHSD17B10HPGDALDH1A1MAPK1 | |
| SCHEMBL1924058 | 0.74 | CSNK2A1 (0.70) | KDM4EHSD17B10HPGDALDH1A1GLA | |
| SCHEMBL1925112 | 0.73 | MAPT (0.55) | KDM4EHSD17B10HPGDALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | KDM4E 3157/4885HSD17B10 2980/4885HPGD 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.